• Skip to content
  • Skip to navigation
  • Skip to footer
AstraZeneca logo AstraZeneca logo
AstraZeneca logo AstraZeneca logo
  • What science can do
    What science can do
    • Stories of impact
    • Publications
  • R&D
    R&D
    • Our approach
      Our approach to R&D
      • Oncology R&D strategy
      • Rare Disease R&D Strategy
      • STEM at AstraZeneca
    • Innovation in medicines
      Innovation in medicines overview
      • Cell therapies
      • Oligonucleotide therapeutics
    • Science & Technologies
      Science & Technologies overview
      • AI and data
      • Genomics
    • Patient Commitment
    • R&D Collaborations
    • Our R&D centres
    Featured website AstraZeneca Clinical Trials Clinical trial website thumbnail Featured website Open Innovation OpenInnovation logo
  • Our therapy areas
    Our therapy areas
    • Oncology
    • BioPharmaceuticals
    • Cardiovascular, Renal and Metabolism
    • Respiratory & Immunology
    • Infectious Disease
    • Rare Disease
    • Pipeline
    • All medicines
  • Our company
    Our company
    • Our history
    • Our leadership
    • Cambridge
    • Gothenburg
    • Gaithersburg
  • Careers
    Careers
    • Great place to work
    • Inclusion and diversity
    • Learning and development
    • Employee resource groups
  • Investors
    Investor Relations (Global)
    • Investor Relations (Sweden)
    • Resources
    • Governance
    • Shareholder information
    • Dividend policy
    • Key facts
    • FAQs
    • Debt Investors
    • Investor Relations contacts
    • Annual Report 2025
    Feature Results and presentations ipad image
  • Media
    Media
    • Press Releases
    • Articles
    • Image library
    • Archive
    • Media contacts
  • Sustainability
    Sustainability
    • Climate change
      Climate change overview
      • Renewables
      • Product sustainability
      • Electric vehicles and Sustainable transport
    • Nature
      Nature overview
      • Water stewardship
      • Pharmaceuticals in the environment
      • Waste and circularity
      • AZ Forest
    • Health equity
      Health equity overview
      • Science
      • Healthcare delivery
      • Community investment
    • Health systems resilience
      Health systems resilience overview
      • Partnership for Health System Sustainability and Resilience (PHSSR)
    • Ethics and governance
      Ethics and Compliance
      • Governance
      • Sustainability governance
    • Our people
      Great place to work
      • Inclusion and diversity
      • Learning and development
      • Workforce safety and health
    • Our Values
    • Partnerships and alliances
    • Resources
      Sustainability resources
      • Our sustainability impact
    Feature Our Sustainability Impact Feature Sustainable science
  • Partnering
    Partnering
    • Our business development teams
    • Our areas of partnering interest
    • Why partner with AstraZeneca?
    • Information for Suppliers
    • Supplier Sustainability Hub
    • Sustainable procurement
    • A Catalyst Network
  • AstraZeneca Websites
  • Global site

Results 51 – 60 of 151 for vaccine Covid (0.04 seconds)

Travelling with COVID-19 Vaccine AstraZeneca made in Thailand

Travelling with COVID-19 Vaccine AstraZeneca made in Thailand

20 August 2021

AZD1222 US Phase III primary analysis confirms safety and efficacy

76% vaccine efficacy against symptomatic COVID-19 100% efficacy against severe or critical disease and hospitalisation 85% efficacy against ...

25 March 2021

New Vaxzevria data further support its use as third dose booster

previously vaccinated with either Vaxzevria or an mRNA vaccine. A separate Phase IV trial reported in a preprint with The Lancet on SSRN showed that a ...

13 January 2022

Development of COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups

Development of COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups

31 August 2020

AstraZeneca and European Commission reach settlement agreement over vaccine supply, ending litigation

AstraZeneca and European Commission reach settlement agreement over vaccine supply, ending litigation

3 September 2021

วัคซีนป้องกันโควิด-19 ของแอสตร้าเซนเนก้าและวัคซีน mRNA ล้วนมีประสิทธิผลเท่ากัน ในการป้องกันการเข้ารักษาตัวในโรงพยาบาลและการเสียชีวิตจากโรคโควิด-19

Health) และศูนย์การเข้าถึงวัคซีนนานาชาติ (International Vaccine Access Center) ...

27 April 2022

Vaxzevria showed no increased incidence of thrombosis with thrombocytopenia after second dose

“Vaxzevria is effective against all severities of COVID-19 and it plays a critical role in combatting the pandemic. Unless TTS was identified after ...

28 July 2021

Vaxzevria induced immunity for at least one year following a single dose and strong immune responses following either a late second dose or a third dose

Pollard, chief investigator and director of the Oxford Vaccine Group at the University of Oxford, said: “This should come as reassuring news to ...

28 June 2021

Vaxzevria highly effective at preventing COVID-19 severe outcomes and death when used as first or second booster, according to new real-world evidence study in Thailand

Vaxzevria highly effective at preventing COVID-19 severe outcomes and death when used as first or second booster, according to new real-world evidence ...

12 December 2022

การศึกษาล่าสุดเผย วัคซีนป้องกันโควิด-19 ของแอสตร้าเซนเนก้า และวัคซีน mRNA มีประสิทธิผลในการป้องกันการเข้ารักษาตัวในโรงพยาบาล และการเสียชีวิตจากโควิด-19 ได้ในระดับสูงไม่แตกต่างกัน

Health) และศูนย์การเข้าถึงวัคซีนนานาชาติ (International Vaccine Access Center) ซึ่งแพลตฟอร์มนี้ได้รับการอัปเดตข้อมูลทุกสัปดาห์ ...

14 July 2022

Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next

AstraZeneca Websites

This website is intended for people seeking information on AstraZeneca's worldwide business. Our country sites can be located in the AZ Network.


Veeva ID: Z4-68564
Date of next review: August 2026

Resources

  • All resources
  • Open Innovation
  • Externally sponsored scientific research
  • Medical Information for HCPs
  • US prescription assistance programmes
  • Global clinical trials information
  • Medicines
  • Report a possible side effect

Quick links

  • Media
  • Investor Relations
  • Partnering
  • Careers
  • Sustainability
  • Modern Slavery Statement
  • AZethics – Report A Concern
  • Supplier information
  • Social Media Community Guidelines

Social Media

  • Linkedn
  • Instagram
  • Facebook
  • Twitter
  • YouTube
  • Glassdoor

utility links

  • Legal notice and Terms of Use
  • Privacy notice
  • Site map
  • Contact us
  • Cookie preferences

© AstraZeneca 2026

You are now leaving AstraZeneca.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.

Cancel Continue

Important notice for users

You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.

I disagree I agree